Akima R., Tsuzuki K., Tokuhiro S., Ue H., Ogawa Y. Experimental study of a new enzyme-targeting radiosensitizer (KORTUC) containing hydrogen peroxide & sodium hyaluronate for intra-tumoral injection using mice transplanted with SCCVII tumor. Jpn J Clin Radiol. 2009; 54: 1683–88. (In Japanese).
Aoyama N, Ogawa Y, Yasuoka M, et al. Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breast cancer. Oncol Lett. 2016; 12(1): 29-34.
Aoyama N, Ogawa Y, Yasuoka M, et al. Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane. Oncol Lett. 2017a; 13(1): 69-76.
Aoyama N, Ogawa Y, Yasuoka M, et al. Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas II, in patients with stage I primary breast cancer. Oncol Lett. 2017b; 13(6):4741-7.
Arriagada R, Mouriesse H, Sarrazin D, Clark RM, Deboer G. Radiotherapy alone in breast cancer. I. Analysis of tumor parameters, tumor dose and local control: the experience of the Gustave-Roussy Institute and the Princess Margaret Hospital. Int J Radiat Oncol Biol Phys. 1985; 11(10): 1751-7.
Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012; 9(3): 193-9.
Brown JM. The hypoxic cell: a target for selective cancer therapy–eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999; 59(23): 5863-70.
Dalton TP, Shertzer HG, Puga A. Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol. 1999; 39:67-101.
Demaria S, Pilones KA, Vanpouille-Box C, Golden EB, Formenti SC. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res. 2014; 182(2): 170-81.
Fang Y, Moore BJ, Bai Q, et al. Hydrogen peroxide enhances radiation-induced apoptosis and inhibition of melanoma cell proliferation. Anticancer Res. 2013; 33(5): 1799-807.
Fujita S, Hosokawa Y, Saga R, et al. Apoptotic induction mechanism of X-ray irradiation combined with hydrogen peroxide. Radiat Environ Med. 2019 8(2): 85-93.
Griendling KK, Harrison DG. Dual role of reactive oxygen species in vascular growth. Circ Res. 1999; 85(6):562-3.
Hammond EM, Asselin MC, Forster D, O’Connor JP, Senra JM, Williams KJ. The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clin Oncol (R Coll Radiol). 2014; 26(5):277-88.
Hayashi N, Ogawa Y, Kubota K, et al. Computed tomography demonstration of the production and distribution of oxygen gas following intratumoral injection of a new radiosensitizer (KORTUC) for patients with breast cancer-Is intratumoral injection not an ideal approach to solve the major problem of tumor hypoxia in radiotherapy? Cancers (Basel). 2016; 8(4): 43.
Hitomi J, Kubota K, Ogawa Y, Hamada N, Murata Y, Nishioka A. Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II). Exp Ther Med. 2010;1(5):769-75.
Kariya S, Sawada K, Kobayashi T, et al. Combination treatment of hydrogen peroxide and X-rays induces apoptosis in human prostate cancer PC-3 cells. Int J Radiat Oncol Biol Phys. 2009; 75(2): 449-54.
Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019; 95(7): 936-39.
Miyatake K, Kubota K, Ogawa Y, Hamada N, Murata Y, Nishioka A. Non-surgical care for locally advanced breast cancer: radiologically assessed therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy. Oncol Rep. 2010; 24(5):1161-8.
Morita-Tokuhiro S, Ogawa Y, Yokota N, et al. Development of a novel enzyme-targeting radiosensitizer (New KORTUC) using a gelatin-based hydrogel instead of a sodium hyaluronate. Cancers (Basel). 2016;8(1): 10.
Mukai H, Watanabe T, Mitsumori M, et al. Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Japan Clinical Oncology Group Study JCOG0306. Oncology. 2013; 85(6): 336-41.
Nishioka A, Ogawa Y, Miyatake K, et al. Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer. Oncol Lett. 2014; 8(1): 404-8.
Obata S, et al. Possibility of a “Sentinel Effect” in Chemo-Radiotherapy and a New Radio-Sensitizer Injection (KORTUC). Jpn J Clin Radiol. 2018; 63: 317-27 (in Japanese).
Ogawa Y, Kubota K, Ue H, et al. Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Int J Oncol. 2009; 34(3): 609-18.
Ogawa Y, Kubota K, Ue H, et al. Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTUC II) for intratumoral injection for low-LET radioresistant tumors. Int J Oncol. 2011; 39(3): 553-60.
Ogawa Y, Kubota K, Aoyama N, et al. Non-surgical breast-conserving treatment (KORTUC-BCT) using a new radiosensitization method (KORTUC II) for patients with Stage I or II breast cancer. Cancers (Basel). 2015;7(4):2277-89.
Ogawa Y et al. Basic and Clinical Research of KORTUC. Tokyo: Shinoharashinsha Publishers; 2015 (in Japanese).
Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007; 25(26): 4066-74.
Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53(5): 1097-105.
Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991; 10(8):2247-58.
Shibamoto Y, Murai T, Suzuki K, et al. Definitive radiotherapy with SBRT or IMRT boost for breast cancer: excellent local control and cosmetic outcome. Technol Cancer Res Treat. 2018;17:1533033818799355.
Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995; 270(5234):296-9.
Tokuhiro S, Ogawa Y, Tsuzuki K, et al. Development of a novel enzyme-targeting radiosensitizer (KORTUC) containing hydrogen peroxide for intratumoral injection for patients with low linear energy transfer-radioresistant neoplasms. Oncol Lett. 2010; 1(6):1025-8.
Tsuzuki A, Ogawa Y, Kubota K, et al. Evaluation of changes in tumor shadows and microcalcifications on mammography following KORTUC II, a new radiosensitization treatment without any surgical procedure for elderly patients with stage I and II breast cancer. Cancers (Basel). 2011; 3(3): 3496-505.
Yaogawa S, Ogawa Y, Morita-Tokuhiro S, et al. Serial assessment of therapeutic response to a new radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in patients with stage I/II breast cancer using breast contrast-enhanced magnetic resonance imaging. Cancers (Basel). 2015; 8(1): 1.
Ye JC, Formenti SC. Integration of radiation and immunotherapy in breast cancer – Treatment implications. Breast. 2018; 38: 66-74.
Samantha Nimalasena , Lone Gothard , et al. Intratumoral Hydrogen Peroxide With Radiation Therapy in Locally Advanced Breast Cancer: Results From a Phase 1 Clinical Trial. Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1019-1029. doi: 10.1016/j.ijrobp.2020.06.022
Mio Nakata , Ken Yoshida , Taiju Shimbo, et al. High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report. J Contemp Brachytherapy. 2020 Dec;12(6):606-611. DOI: 10.5114/jcb.2020.101695